Vercirnon（クローン病治療薬）：市場予測及び分析（～2022）...市場調査レポートについてご紹介

1 Table of Contents
1 Table of Contents 5
1.1 List of Tables 7
1.2 List of Figures 8
2 Introduction 9
2.1 Catalyst 9
2.2 Related Reports 10
2.3 Upcoming Related Reports 11
3 Disease Overview 12
3.1 Etiology and Pathophysiology 12
3.1.1 Etiology 12
3.1.2 Pathophysiology 12
3.2 Symptoms 16
3.3 Prognosis 17
3.4 Quality of Life 17
4 Disease Management 18
4.1 Treatment Overview 19
5 Competitive Assessment 24
5.1 Overview 24
5.2 Strategic Competitor Assessment 25
6 Opportunity and Unmet Need 27
6.1 Overview 27
6.2 Physicians Desire Biomarkers That Will Allow a Personalized Treatment Approach 28
6.3 More Therapies for Anti-TNF-Refractory Patients 29
6.4 Unmet Needs Gap Analysis 30
6.5 Targeted Therapies 31
6.6 Predictive Tools for Early Diagnosis and Treatment 32
7 Pipeline Assessment 33
7.1 Overview 33
7.2 Promising Drugs in Clinical Development 33
8 Vercirnon (formerly GSK1605786) 36
8.1 Overview 36
8.2 Efficacy 37
8.3 Safety 39
8.4 Dosing and Formulation 39
8.5 Potential Clinical Positioning 40
8.6 Potential Commercial Positioning 40
8.7 Pricing and Reimbursement 41
8.8 SWOT Analysis 42
8.9 Forecast 42
9 Appendix 44
9.1 Bibliography 44
9.2 Abbreviations 48
9.3 Methodology 50
9.4 Forecasting Methodology 50
9.4.1 Diagnosed CD Patients 50
9.4.2 Percent Drug-Treated Patients 51
9.4.3 General Pricing Assumptions 51
9.4.4 Generic Erosion 52
9.4.5 Pricing of Pipeline agents 53
9.5 Physicians and Specialists Included in This Study 53
9.6 Primary Research – Prescriber Survey 55
9.7 About the Authors 56
9.7.1 Author/Reviewer 56
9.7.2 Global Head of Healthcare 56
9.8 About GlobalData 57
9.9 Disclaimer 57